Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Overall, we are pleased with the early commercial experience with Quell Fibromyalgia and we hope to see continued progress leading to material revenue this year |
| Nevertheless, we expect the DPNCheck business line will continue to generate positive cash flow by virtue of its attractive operating margins |
| We are pleased with the growth in the Quell Fibromyalgia business in the fourth quarter of last year |
| The balance of our Q4 revenue reflects offsetting dynamics of Quell Fibromyalgia revenue growth on the upside, nearly doubling from Q3 to the sequential quarter and continuing revenue shrinkage in our legacy products, primarily consisting of electrode sales for nerve conduction testing by long-time customers |
| Of course, we are also mindful of the divergence between our stock price and the potential of our product line is a strong balance sheet |
| While the company management and the Board are disappointed by the impact of external forces on DPNCheck, we remain enthusiastic about the potential for our Quelle Neuromodulation business and, in fact, also our DPNCheck business |
| We also reported positive results from a pilot study of Quell in post-acute COVID-19 syndrome, which is also called long COVID |
| We have been focused on the diabetes market within Medicare Advantage, because of the strong clinical benefits, as well as the economic benefits to the medical groups that were using it and many continue to use it |
| The business had been growing for several years |
| The net loss increased by $1 million from a net loss of just under $700,000 a or $0.73 a share in Q4 of last year |
| The second is to advance the Quell Neurotherapeutics program, which will lead to additional indications in an expanded addressable market |
| For the full-year, our net loss of $6.5 million or $6.27 per share increased from a loss in 2022 of $4.4 million or $4.97 per share |
| Full-year OpEx of $11.1 million increased by $600,000 or 5.8% from 2022 |
| And the number of month refills increased from 315 in the third quarter of last year to 525 in the fourth quarter |
| Thank you for your attention |
| So they do need to be compensated for their time and the materials in some fashion, and that was well established in the Medicare Advantage market |
| Joshua Horowitz Good morning |
| Thank you |
| Thomas Higgins Well, thank you very much for your input |
| Now in terms of the overall Quell Neurotherapeutics program it is the second element of our growth strategy, and that is to increase our pipeline beyond the Fibromyalgia indication |
| We are currently exploring various alternate markets within value-based care and retail health care and attempt to reconstitute a profitable, scalable business model |
| Statement |
|---|
| For the full-year 2023, revenue of $5.9 million was down by 29% from $8.3 million in 2022, principally due to the Medicare Advantage CMS rule changes |
| As we saw this quarter, the Medicare Advantage changes have caused a material downward pressure on DPNCheck revenues |
| The gross profit reduction of about $400,000 from $1.2 million in Q4 of last year, correlates with the drop in revenue |
| For the full-year 2023, gross profit was $3.9 million at a margin rate of about 67%, down by $1.8 million from $5.8 million in 2022 at a margin rate of just under 70% |
| Our Q4 gross margin rate was 64.4%, a slight contraction from the prior year quarter, reflecting a reduction in the absorption of indirect manufacturing costs, which resulted from lower production problem -- lower production volumes |
| It was down by 32% from Q4 of last year |
| Net loss in Q4 was $1.6 million or $1.43 per share |
| On a full-year basis, this business contracted by 25% |
| And as we've discussed in prior quarters, this significant decline was attributable to the Medicare Advantage CMS rule changes in early 2023, which initiated a two-year timetable to phase out reimbursement for a range of patient screening, including peripheral neuropathy |
| The only FDA-approved drugs are pregabalin, duloxetine and milnacipran which can have substantial side effects |
| It's a pretty ridiculous structure, and it sort of makes the company uninvestable |
| Implementation of new strategies will take time, and therefore, we do not see a reversal in revenue this year |
| However, substantial uncertainty was injected into the Medicare Advantage sector last year due to policy changes announced by the Centers for Medicare and Medicaid Services, or CMS |
| You should not rely on forward-looking statements because actual results may differ materially as a result of a number of important factors, including those set forth in the earnings release issued earlier today |
| And the third is to revise the DPNCheck business strategy to account for the recent negative changes [Technical Difficulty] Quell is our wearable Neuromodulation platform |
Please consider a small donation if you think this website provides you with relevant information